Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Goldman Sachs analyst David Roman upgrades Beta Bionics (NASDAQ:BBNX) from Neutral to Buy and raises the price target from $...
Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from ...
Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from ...
Baird analyst Jeff Johnson maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and raises the price target from $15 to $17.
Beta Bionics (NASDAQ:BBNX) raises FY2025 sales outlook from $82.00 million-$87.00 million to $88.00 million-$93.00 million vs $...
Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.47) ...
